QIAGEN partners with CMM to support breast cancer research

QIAGEN is working with the Centre for Molecular Medicine (CMM) to support research into the discovery of molecular biomarkers capable of helping diagnose breast cancer and other women’s health issues.

The molecular diagnostics company will utilise the Van Andel Research Institute’s XenoBase database system, which is capable of analysing a wide range of molecular and conventional clinical data – helping researchers identify clinically actionable associations between diseases, biomarkers and treatments.

Based on QIAGEN’s initial research, the CMM may provide laboratory-based genomics and proteomics services to assist with the development of new molecular diagnostic tests.

Daniel Farkas, executive director of CMM, said: "CMM is pleased that QIAGEN, a global leader in molecular diagnostics, recognizes the value of software-driven biomarker research and how advanced the resources in West Michigan truly are in this rapidly emerging fields."

QIAGEN is a leading supplier of sample and assay technologies. It employs more than 2,600 people worldwide.